Cargando…
Hydroxyurea-Loaded Albumin Nanoparticles: Preparation, Characterization, and In Vitro Studies
Human serum albumin nanoparticles (HSA-NPs) have been widely used as drug delivery systems. In most cases, HSA-NPs are formed by the method of desolvation in the presence of glutaraldehyde as a crosslinking agent. In the present study, we showed the possibility of crosslinking human serum albumin (H...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6723891/ https://www.ncbi.nlm.nih.gov/pubmed/31409024 http://dx.doi.org/10.3390/pharmaceutics11080410 |
_version_ | 1783448875954077696 |
---|---|
author | Tazhbayev, Yerkeblan Mukashev, Olzhas Burkeev, Meiram Kreuter, Jörg |
author_facet | Tazhbayev, Yerkeblan Mukashev, Olzhas Burkeev, Meiram Kreuter, Jörg |
author_sort | Tazhbayev, Yerkeblan |
collection | PubMed |
description | Human serum albumin nanoparticles (HSA-NPs) have been widely used as drug delivery systems. In most cases, HSA-NPs are formed by the method of desolvation in the presence of glutaraldehyde as a crosslinking agent. In the present study, we showed the possibility of crosslinking human serum albumin (HSA) molecules with natural agents, urea, and cysteine at the nanoparticle level under mild conditions (at room temperature of 20–25 °C). Optimal concentrations of the interacting components (HSA, urea, and cysteine) were found to produce nanoparticles with optimal physico-chemical parameters (particle size, polydispersity, zeta potential, yield, etc.) for application as drug carriers. We used hydroxyurea (HU), a simple organic compound currently used as a cancer chemotherapeutic agent. The results indicated sizes of 196 ± 5 nm and 288 ± 10 nm with a surface charge of −22 ± 3.4 mV and −17.4 ± 0.5 mV for HSA-NPs (20 mg/mL of HSA, 0.01 mg/mL of cysteine, and 10 mg/mL of urea) and HSA–HU-NPs (2 mg/mL of HU), respectively. The yield of the HSA–HU-NPs was ~93% with an encapsulation efficiency of ~77%. Thus, the particles created (immobilized with HU) were stable over time and able to prolong the effect of the drug. |
format | Online Article Text |
id | pubmed-6723891 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-67238912019-09-10 Hydroxyurea-Loaded Albumin Nanoparticles: Preparation, Characterization, and In Vitro Studies Tazhbayev, Yerkeblan Mukashev, Olzhas Burkeev, Meiram Kreuter, Jörg Pharmaceutics Article Human serum albumin nanoparticles (HSA-NPs) have been widely used as drug delivery systems. In most cases, HSA-NPs are formed by the method of desolvation in the presence of glutaraldehyde as a crosslinking agent. In the present study, we showed the possibility of crosslinking human serum albumin (HSA) molecules with natural agents, urea, and cysteine at the nanoparticle level under mild conditions (at room temperature of 20–25 °C). Optimal concentrations of the interacting components (HSA, urea, and cysteine) were found to produce nanoparticles with optimal physico-chemical parameters (particle size, polydispersity, zeta potential, yield, etc.) for application as drug carriers. We used hydroxyurea (HU), a simple organic compound currently used as a cancer chemotherapeutic agent. The results indicated sizes of 196 ± 5 nm and 288 ± 10 nm with a surface charge of −22 ± 3.4 mV and −17.4 ± 0.5 mV for HSA-NPs (20 mg/mL of HSA, 0.01 mg/mL of cysteine, and 10 mg/mL of urea) and HSA–HU-NPs (2 mg/mL of HU), respectively. The yield of the HSA–HU-NPs was ~93% with an encapsulation efficiency of ~77%. Thus, the particles created (immobilized with HU) were stable over time and able to prolong the effect of the drug. MDPI 2019-08-12 /pmc/articles/PMC6723891/ /pubmed/31409024 http://dx.doi.org/10.3390/pharmaceutics11080410 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Tazhbayev, Yerkeblan Mukashev, Olzhas Burkeev, Meiram Kreuter, Jörg Hydroxyurea-Loaded Albumin Nanoparticles: Preparation, Characterization, and In Vitro Studies |
title | Hydroxyurea-Loaded Albumin Nanoparticles: Preparation, Characterization, and In Vitro Studies |
title_full | Hydroxyurea-Loaded Albumin Nanoparticles: Preparation, Characterization, and In Vitro Studies |
title_fullStr | Hydroxyurea-Loaded Albumin Nanoparticles: Preparation, Characterization, and In Vitro Studies |
title_full_unstemmed | Hydroxyurea-Loaded Albumin Nanoparticles: Preparation, Characterization, and In Vitro Studies |
title_short | Hydroxyurea-Loaded Albumin Nanoparticles: Preparation, Characterization, and In Vitro Studies |
title_sort | hydroxyurea-loaded albumin nanoparticles: preparation, characterization, and in vitro studies |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6723891/ https://www.ncbi.nlm.nih.gov/pubmed/31409024 http://dx.doi.org/10.3390/pharmaceutics11080410 |
work_keys_str_mv | AT tazhbayevyerkeblan hydroxyurealoadedalbuminnanoparticlespreparationcharacterizationandinvitrostudies AT mukashevolzhas hydroxyurealoadedalbuminnanoparticlespreparationcharacterizationandinvitrostudies AT burkeevmeiram hydroxyurealoadedalbuminnanoparticlespreparationcharacterizationandinvitrostudies AT kreuterjorg hydroxyurealoadedalbuminnanoparticlespreparationcharacterizationandinvitrostudies |